Abstract:Introduction: Japanese encephalitis virus (JEV) and Zika virus (ZIKV) pose a severe threat to human health. Our previous research results, as well as those of other research groups, indicated that antibodies (Abs) induced by JEV infection or JEV vaccine vaccination could enhance ZIKV infection in vitro and exacerbate the mortality of ZIKV-infected mice, vice versa, which is known as antibody-dependent enhancement (ADE). Although studies on other flaviviruses revealed that altering the amino acid residues located in the fusion loop (FL) of envelope (E) protein can reduce the level of flavivirus-cross-reactive Abs, thereby abating the ADE of heterologous flavivirus infection, it is unclear whether this strategy is equally applicable to JEV. Methods: In this study, we constructed recombinant adenoviruses and nucleotide-modified mRNA-lipid nanoparticle (LNP) encoding JEV wild-type E protein or E protein mutant (designated as Ad5-JEV-E WT and Ad5-JEV-E mut ; JEV-E WT mRNA-LNP, and JEV-E mut mRNA-LNP). We evaluated the immunogenicity of these vaccine candidates in mice and the capacity of vaccine-immune mouse sera to neutralize JEV infection or mediate ADE of ZIKV infection in vitro and in vivo . Results: Ad5-JEV-E mut or JEV-E mut mRNA-LNP immunization induced ZIKV-cross-reactive Ab response which is dramatically lower than that induced by Ad5-JEV-E WT and JEV-E WT mRNA-LNP, respectively. The levels of JEV-neutralizing Abs induced by Ad5-JEV-E mut or JEV-E mut mRNA-LNP are comparable to that induced by Ad5-JEV-E WT and JEV-E WT mRNA-LNP, respectively. The ability of Abs induced by Ad5-JEV-E mut to enhance ZIKV infection in vitro is attenuated as compared with that induced by Ad5-JEV-E WT . Moreover, JEV-E mut mRNA-LNP immunization elicited potent T cell response similar to JEV-E WT mRNA-LNP in mice. Mice immunized with each mRNA-LNP exhibited lower level of serum viral load than the mock-immunized mice post JEV challenge. Mice receiving JEV-E WT mRNA-LNP-immune mouse sera exhibited ADE post ZIKV challenge whereas passively transferred JEV-E mut mRNA-LNP-immune mouse sera did not lead to obvious ADE of ZIKV infection in recipient mice. Most importantly, maternally acquired Abs did not enhance the mortality of 1-day-old neonates born to JEV-E mut mRNA-LNP-immunized mice post ZIKV challenge. Discussion: These results suggest that optimizing the FL sequence of JEV could significantly reduce the level of JEV/ZIKV-cross-reactive Abs and abrogate the ADE of ZIKV infection, providing a promising strategy to develop effective and safety JEV vaccine.

Lentivirus-mediated RNA Interference Against Japanese Encephalitis Virus Infection in Vitro and in Vivo.

Effective Inhibition of Japanese Encephalitis Virus Replication by Shrnas Targeting Various Viral Genes in Vitro and in Vivo.

Lentiviral Vector-Derived Shrnas Confer Enhanced Suppression of Semliki Forest Virus Replication in Bhk-21 Cells Compared to Shrnas Expressed from Plasmids

Effective inhibition of Japanese encephalitis virus replication by small interfering RNAs targeting the NS5 gene.

The NS3 and NS4A Genes As the Targets of RNA Interference Inhibit Replication of Japanese Encephalitis Virus in Vitro and in Vivo.

Inhibition of Japanese Encephalitis Virus NS1 Protein Expression in Cell by Small Interfering RNAs

Inhibition of Japanese Encephalitis Replication in Cells by Small Interfering RNAs

Cellular Interleukin Enhancer-Binding Factor 2, ILF2, Inhibits Japanese Encephalitis Virus Replication In Vitro

In Vitro Inhibition of Japanese Encephalitis Virus Replication by Capsid-Targeted Virus Inactivation

An engineered Japanese encephalitis virus mRNA-lipid nanoparticle immunization induces protective immunity in mice

Rna Interference Screening Reveals Requirement For Platelet-Derived Growth Factor Receptor Beta In Japanese Encephalitis Virus Infection

Autophagy inhibitors alleviate Japanese encephalitis virus-induced cerebral inflammation in mice

MicroRNA-19b-3p Modulates Japanese Encephalitis Virus-Mediated Inflammation via Targeting RNF11

Protective Immune Responses Induced by an Mrna-Lnp Vaccine Encoding Prm-E Proteins Against Japanese Encephalitis Virus Infection

Etanercept Reduces Neuroinflammation And Lethality In Mouse Model Of Japanese Encephalitis

Degradation of MicroRNA Mir-466D-3p by Japanese Encephalitis Virus NS3 Facilitates Viral Replication and Interleukin-1β Expression

SLC25A12 inhibits Japanese encephalitis virus replication by interacting with the NS1 and enhancing the type I interferon response

Microrna-15b Modulates Japanese Encephalitis Virus-Mediated Inflammation Via Targeting Rnf125

Structural basis for neutralization of Japanese encephalitis virus by two potent therapeutic antibodies

Japanese Encephalitis Virus NS5 Inhibits Type I Interferon (IFN) Production by Blocking the Nuclear Translocation of IFN Regulatory Factor 3 and NF-κB.

Mir-124 Attenuates Japanese Encephalitis Virus Replication by Targeting DNM2